Clinical Trials: Thromboembolism

Montgomery : Baptist Health

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Glendale : Arrowhead Hospital/Phoenix Heart, PLLC

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Little Rock : Arkansas Children's Hospital Research Institute

Treatment of Blood Clots in Children With Cancer

Modesto : Memorial Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Orange : St. Joseph Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Palo Alto : Stanford University Medical Center

Treatment of Blood Clots in Children With Cancer

San Diego :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Stanford : Stanford University Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

View More »

Stanford : Stanford University Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Danbury : Danbury Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Hartford : Hartford Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Norwich : Eastern Connecticut Hematology and Oncology Associates

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Newark : Christiana Care Health Systems

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Washington : Georgetown University Lombardi Cancer Center

Treatment of Blood Clots in Children With Cancer

Jacksonville : Nemours Children's Clinic/Jacksonville

Treatment of Blood Clots in Children With Cancer

Melbourne : Holmes Regional Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Orlando : Orlando Regional Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Orlando : Florida Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Orlando : Florida Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

View More »

Tampa : Pepin Heart Hospital / University Community Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Tampa : St. Joseph's Children's Hospital of TampaPediatric Hematology/Oncology Research Department

Treatment of Blood Clots in Children With Cancer

Vero Beach :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Atlanta : Emory University

Treatment of Blood Clots in Children With Cancer

Macon : Medical Center of Central Georgia

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Chicago : University of Illinois at Chicago

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Chicago : Rush University Medical Center

Treatment of Blood Clots in Children With Cancer

Hinsdale : Adventist Midwest Health

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Springfield : Prairie Heart Institue

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Springfield : Prairie Education and Research Cooperative

A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis

View More »

Springfield : Southern Illinois University

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Winfield : Central DuPage Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Indianapolis : St. Vincent Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Indianapolis : CorVasc

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Iowa City : University of Iowa Carver's College of Medicine

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Florence : St. Elizabeth Healthcare of Northern Kentucky

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Lexington : University of Kentucky, Gill Heart Institute

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Louisvile : Kosair Charities Pediatric Clinical Research Unit- University of Louisville

Treatment of Blood Clots in Children With Cancer

New Orleans : East Jefferson General Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Portland : Maine Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Boston : Massachusetts General Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Ann Arbor : Ann Arbor Veteran's Administration Health System

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Ann Arbor : University of Michigan Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Detroit : Henry Ford Health System

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Detroit : Detroit Medical Center

Fondaparinux in Critically Ill Patients With Renal Failure

Rochester : Mayo Clinic

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

St. Louis : Washington University School of Medicine

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Butte :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Lincoln : Saint Elizabeth Regional Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Morristown : Overlook Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Teaneck : Holy Name Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Teaneck : Holy Name Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Albuquerque : University of New Mexico

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Albuquerque : University of New Mexico

Treatment of Blood Clots in Children With Cancer

Buffalo : Roswell Park Cancer Institute

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

New York : Cornell Weill Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Rochester : Rochester General Hospital

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Rochester : University of Rochester Medical Center

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Staten Island : Staten Island University Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Chapel Hill : University of North Carolina at Chapel Hill

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Durham : Duke University School of Medicine

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Durham : Duke University

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

Durham : Duke Children's Hospital

Treatment of Blood Clots in Children With Cancer

Winston Salem : Wake Forest University Baptist Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

View More »

Winston-Salem : Forsyth Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Cincinatti : Good Samaritan Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Cleveland : Cleveland Clinic

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Colombus : Univeristy Medical Center

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Columbus : Mt. Carmel East

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Columbus : Riverside Methodist Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

View More »

Toledo : Jobst Vascular Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Portland : Oregon Health & Science University

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Portland : Oregon Health and Science University

Treatment of Blood Clots in Children With Cancer

Bethlehem : St. Luke's Hospital and Health Network

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Philadelphia : Albert Einstein Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Philadelphia : Temple University Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Pittsburgh : Allegheny General Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Pittsburgh : The Western Pennsylvania Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

View More »

Pittsburgh : University of Pittsburgh Medical Center Presbyterian Shadyside

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

West Reading : The Reading Hospital and Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Providence : Rhode Island Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Charleston : Medical University of South Carolina

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Charleston : Medical Center of South Carolina

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Memphis : St. Jude Children's Research Hospital

Treatment of Blood Clots in Children With Cancer

El Paso : Providence Memorial and Sierra Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Forth Worth : Cook Children's Medical Center

Treatment of Blood Clots in Children With Cancer

Salt Lake City : University of Utah

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Alexandria : Inova Alexandria Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Charlottesville : University of Virginia Health System

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Tacoma : MultiCare Health System

A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).

Milwaukee : Medical College of Wisconsin/Froedtert Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Graz : 1160.86.43001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Wien : 1160.84.4310 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Wien : 1160.84.4301 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Wien : 1160.89.43001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

View More »

Wien : 1160.86.43003 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Brussel : 1160.89.32003 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Valinhos : LAL Clinica Pesquisa e Desenvolvimento Ltda

Efficacy And Safety Of Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass

Valinhos : LAL Clinica Pesquisa e Desenvolvimento Ltda

Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass

Valinhos : Lal Clinica Pesquisa E Desenvolvimento Ltda

Efficacy of Sodium Heparin in Prophylaxis of Venous Thromboembolism in Surgical Patients

Charlottetown : 1160.86.01003 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Edmonton : 1160.89.00002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Halifax : QE II Health Sciences Centre

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Hamilton : Hamilton Health Sciences Corporation-General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Hamilton : Hamilton Health Sciences Corporation-Henderson Site

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

View More »

Hamilton : Hamilton Health Sciences Corporation-McMaster Site

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Montreal : SMBD Jewish General Hospital

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

Montreal : Montreal General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Montreal : SMBD Jewish General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Montréal : Maisonneuve Rosemont Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Oshawa : Isis Investigational Site

Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS FXI Rx in Total Knee Arthroplasty

Ottawa : Ottawa Health Research Institute

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

Ottawa : Ottawa Hospital-General Campus

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Ottawa : 1160.89.00001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Red Deer : 1160.86.01001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Saskatoon : Saskatchewan Drug Research Institute

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

Toronto : University Health Network - Toronto General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Toronto : 1160.89.00005 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Vancouver : Diamond Health Care Centre

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

Brno : 1160.86.42001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Olomouc : 1160.86.42003 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Prague : 1160.86.42004 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Prague 5 : 1160.86.42002 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Jyväskylä : 1160.86.35801 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Angers : 1160.84.3311 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Bois Guillaume Cédex : 1160.84.3318 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Bordeaux : 1160.84.3334 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Brest : HIA Clermont-Tonnerre

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Brest : Medical Intensive Care Unit

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

View More »

Caen Cedex 5 : 1160.84.3303 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Castelnau Le Lez : Clinique du Parc CASTELNAU LE LEZ

National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients

Clermont-Ferrand cedex 1 : 1160.84.3314 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Creteil : 1160.84.3320 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Dijon : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

DIJON Cédex : 1160.84.3307 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Grenoble : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Illkirch : 1160.84.3310 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Le Havre : 1160.84.3335 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Les Lilas : 1160.84.3326 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Lille : Medical Intensive Care Unit

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Lille cedex : 1160.84.3304 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Lyon : 1160.84.3312 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Marseille : 1160.84.3305 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Marseille : 1160.89.33002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

MARSEILLE Cédex 05 : 1160.84.3330 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Metz : 1160.84.3325 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Montauban : 1160.84.3333 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Nancy : Département d'Anesthésiologie Hôpital de Brabois

Thromboprophylaxis and Bariatric Surgery

Nancy : Laboratoire d'Hémostase Hôpital de Brabois

Thromboprophylaxis and Bariatric Surgery

Nancy : Service de Chirurgie Digestive Hôpital de Brabois

Thromboprophylaxis and Bariatric Surgery

Nantes : Service de chirurgie générale et digestive,Hôpital Hôtel Dieu

Thromboprophylaxis and Bariatric Surgery

Nantes Cédex 2 : 1160.84.3323 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Paris : Medical Intensive Care Unit

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Paris : 1160.84.3327 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Paris : 1160.84.3302 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Paris : 1160.84.3306 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Paris : 1160.89.33001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Paris cedex 10 : 1160.84.3309 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Pierre Bénite cedex : 1160.84.3313 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Poitiers Cédex : 1160.84.3324 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Saint Etienne Cédex 2 : 1160.84.3322 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Saint Herblain Cédex : 1160.84.3321 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Saint Saulve : 1160.84.3319 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Strasbourg : Centre investigation Clinique Hôpital Civil

Thromboprophylaxis and Bariatric Surgery

Strasbourg : Clinique de l'Orangerie

Thromboprophylaxis and Bariatric Surgery

Strasbourg : Département d'Anesthésiologie Hôpital Civil

Thromboprophylaxis and Bariatric Surgery

Strasbourg : Laboratoire d'hémostase Hôpital de Hautepierre

Thromboprophylaxis and Bariatric Surgery

Strasbourg : Service de Chirurgie Digestive Hopital de Hautepierre

Thromboprophylaxis and Bariatric Surgery

Strasbourg : Service de Chirurgie Générale et Endocrinienne Hôpital Civil

Thromboprophylaxis and Bariatric Surgery

Toulouse Cedex 9 : 1160.84.3317 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Toulouse Cédex 9 : 1160.84.3316 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Vannes Cédex : 1160.84.3332 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Garmisch-Partenkirchen : 1160.84.04912 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Gelnhausen : 1160.84.4922 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Münster : 1160.84.04951 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Olsberg : 1160.84.04913 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Hyderabad : Care Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Many Locations :

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty

New Delhi : Sir Ganga Ram Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Bologna : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Latina : 1160.84.03908 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Milan : IRCCS H San Raffaele

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Milano : 1160.84.03902 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Milano : 1160.84.03905 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

View More »

Monza : 1160.84.03903 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Monza : 1160.84.03904 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Roma : 1160.89.39001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Rozzano (mi) : 1160.84.03906 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Udine : 1160.84.03909 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Many Locations :

Xarelto Regulatory Post-Marketing Surveillance

Riga : 1160.89.37101 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Vilnius : 1160.89.37001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Nijmegen : 1160.89.31003 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Utrecht : 1160.89.31004 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Bergen : 1160.89.47001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Alicante : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Badalona (Barcelona) : 1160.84.3409 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Barcelona : 1160.84.3410 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Linares, Jaén : 1160.84.3413 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Madrid : 1160.84.3403 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

View More »

Madrid : 1160.84.3408 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Madrid : 1160.89.34001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Madrid : 1160.89.34002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Malaga : 1160.84.3405 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Pamplona : 1160.84.3404 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Pozuelo de Alarcón - Madrid : 1160.84.3412 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Soria : General Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Valencia : 1160.84.3411 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Valencia : 1160.84.3401 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Zaragoza : 1160.84.3402 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Hässleholm : 1160.86.46002 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Kungälv : 1160.84.4603 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Mölndal : 1160.86.46001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Motala : 1160.84.4601 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

View More »

Stockholm : Karolinska University Hospital

Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture

Geneva : Hopitaux Universitaires de Geneve

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Zürich : 1160.89.41001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Bangkok : 1160.89.66001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Dnipropetrovsk : 1160.89.38001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Lugansk : 1160.89.38002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Vinnytsya : 1160.89.38003 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Basildon : 1160.84.04405 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Bedford : 1160.84.04408 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Luton : 1160.84.04403 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Wigan : 1160.84.04401 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Yeovil : 1160.84.04407 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Many Locations :

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty